title: Persistent vulvovaginal candidiasis: systemic treatment with oral fluconazole.
abstract: 52 patients affected by persistent vulvovaginal candidiasis underwent systemic therapy with oral Fluconazole at a dose of 150 mg once a week for 3 weeks. 31 (59.61%) patients were cured at the first control after therapy. Of the remaining 21 patients, 4 (7.69%) were lost at follow-up and 17 (32.69%) underwent a second cycle of systemic therapy with complete recovery confirmed at the further controls. The overall percentage of recoveries was equal to 92.30%. The results suggest that Fluconazole is very effective in mycotic vulvovaginitis with irrelevant side effects.
authors.affiliation: II Clinics of Obstetrics and Gynecology, University of Rome, La Sapienza, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Frega
authors.forename: G
authors.initials: G
authors.lastname: Gallo
authors.forename: F
authors.initials: F
authors.lastname: Di Renzi
authors.forename: G
authors.initials: G
authors.lastname: Stolfi
authors.forename: P
authors.initials: P
authors.lastname: Stentella
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D015725:Fluconazole